Partitioning of cancer therapeutics in nuclear condensates

Journal: Science

Published: 2020-06-19

DOI: 10.1126/science.aaz4427

Affiliations: 23

Authors: 32

Go to article
Institutions Share
MIT Whitehead Institute for Biomedical Research, United States of America (USA) 0.45
MIT Department of Biology, United States of America (USA) 0.14
Department of Biochemistry, CU-Boulder, United States of America (USA) 0.06
Department of Cancer Biology, DFCI, United States of America (USA) 0.05
Harvard Department of Biological Chemistry and Molecular Pharmacology (BCMP), United States of America (USA) 0.05
Max Planck Institute for the Physics of Complex Systems (MPIPKS), Germany 0.04
Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG), Germany 0.03
MIT Department of Chemical Engineering (ChemE), United States of America (USA) 0.02
MIT Institute for Medical Engineering and Science (IMES), United States of America (USA) 0.02
MIT David H. Koch Institute for Integrative Cancer Research, United States of America (USA) 0.02
Department of Medicine, MGH, United States of America (USA) 0.02
Dana-Farber Cancer Institute (DFCI), United States of America (USA) 0.02
Department of Chemistry, POSTECH, South Korea 0.02
Center for Self-Assembly and Complexity (CSC), IBS, South Korea 0.02
Cluster of Excellence - Physics of Life (PoL), TU Dresden, Germany 0.02
Harvard Medical School (HMS), United States of America (USA) 0.01
Department of Neurosurgery, MGH, United States of America (USA) 0.01
Center for Systems Biology Dresden (CSBD), Germany 0.01
MIT Department of Physics, United States of America (USA) 0
MIT Department of Chemistry, United States of America (USA) 0
MIT Department of Biological Engineering (BE), United States of America (USA) 0
Ragon Institute of MGH, MIT and Harvard, United States of America (USA) 0

Return